Sonoma Pharmaceuticals Inc. (SNOA)

The total asset value of Sonoma Pharmaceuticals Inc. (SNOA) stood at $ 17 Mln as on 30-Sep-23

The share price of Sonoma Pharmaceuticals Inc. (SNOA) is $0.18 (NASDAQ) as of 08-Dec-2023 16:01 EST. Sonoma Pharmaceuticals Inc. (SNOA) has given a return of -69.79% in the last 3 years.

Sonoma Pharmaceuticals Inc. (SNOA) has a market capitalisation of $ 2 Mln as on 08-Dec-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Sonoma Pharmaceuticals Inc. (SNOA) is 0.44 times as on 08-Dec-2023, a -0.84% premium to its peers’ median range of 2.82 times.

Since, TTM earnings of Sonoma Pharmaceuticals Inc. (SNOA) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sonoma Pharmaceuticals Inc. (SNOA) and enter the required number of quantities and click on buy to purchase the shares of Sonoma Pharmaceuticals Inc. (SNOA).

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

The CEO & director of Ms. Amy M. Trombly. is Sonoma Pharmaceuticals Inc. (SNOA), and CFO & Sr. VP is Mr. Bruce Thornton.

The promoters of Sonoma Pharmaceuticals Inc. (SNOA) have pledged 0% of the total equity as on Sep-23.

Some of the close peers are:

No, TTM profit after tax of Sonoma Pharmaceuticals Inc. (SNOA) was $-5 Mln.